SLC16A1 and Familial prostate cancer: Our results demonstrate for the first time the functional role of SLC16A1 in the transport of afatinib in prostate cancer cells as pharmacological blockage of the transporter by the specific inhibitor BAY-8002 could prevent, at least partially, the sensitization of 22Rv1 cells stably expressing PXR to this kinase inhibitor.